Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy Of Abbreviated Induction With Only 4 Cycles Of Fludarabine (F), Cyclophosphamide (C) and Rituximab (R) In Physically Fit Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Early Complete Remission (CR) With Undetectable Minimal Residual Disease (MDR)

Carolina Pavlovsky, Astrid Pavlovsky, Isolda Fernandez, Adriana Galeano, Francisco Lastiri, Santiago Pavlovsky

Blood (2013) 122 (21): 2886.

https://doi.org/10.1182/blood.V122.21.2886.2886

Published: 2013

Journal Articles

PET -CT Adapted Therapy After 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma. Preliminary Results in 193 Patients

Astrid Pavlovsky, Isolda Fernandez, Virginia Prates, Miguel A Pavlovsky, Lucia Zoppegno, Ana Lisa Basquiera, Federico Sackmann, Francisco Lastiri, Gustavo Milone, Santiago Pavlovsky

Blood (2011) 118 (21): 1619.

https://doi.org/10.1182/blood.V118.21.1619.1619

Published: 2011

Journal Articles

PET-CT Adapted Therapy After 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma. Interim Analysis in 173 Patients

Santiago Pavlovsky, Astrid Pavlovsky, Isolda Fernandez, Miguel Pavlovsky, Virginia Prates, Lucia Zoppegno, Ana Lisa Basquiera, Ider Cerutti, Andrea Rodriguez, Gustavo Milone, Vanesa Castano, Silvia Rudoy, Federico Sackmann, Lourdes Valles, Francisco Lastiri

Blood (2010) 116 (21): 1772.

https://doi.org/10.1182/blood.V116.21.1772.1772

Published: 2010

Journal Articles

Prospective Evaluation of the International Prognostic Score (IPS) in All Stages of Hodgkin’s Lymphoma Treated with ABVD Plus Involved-Field Radiotherapy (IFRT).

Santiago Pavlovsky, Claudia Corrado, Miguel A Pavlovsky, Virginia Prates, Lucia Zoppegno, Mario Giunta, Ider Cerutti, Elsa Palomino, Graciela Avila, Francisco Lastiri

Blood (2008) 112 (11): 1454.

https://doi.org/10.1182/blood.V112.11.1454.1454

Published: 2008

Journal Articles

PET-CT Adapted Therapy after 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma. Interim Analysis. Preliminary Results in 102 Patients

Astrid Pavlovsky, Santiago Pavlovsky, Isolda Fernandez, Lucia Zoppegno, Ider Cerutti, Miguel Arturo Pavlovsky, Virginia Prates, Ana Basquiera, Claudia Corrado, Gustavo Milone, Maria Cabrejo, Horacio Fernandez Grecco, Graciela Avila, Viviana Flores Dutrus, Karina Gumpel, Vanina Cabanne, Silvia Saba, Francisco Lastiri

Blood (2008) 112 (11): 2592.

https://doi.org/10.1182/blood.V112.11.2592.2592

Published: 2008

Journal Articles

Fludarabine, Mitoxantrone and Dexamethasone for the First Line Treatment of Patients with Indolent Non-Hodgkin Lymphoma (NHL): GATLA First Interim Report (Grupo Argentino de Tratamiento de la Leucemia Aguda) .

Gustavo Milone, MD, A. Rodriguez, MD, Jorge Milone, MD, R.F. Bezares, MD, S. Rudoy, MD, Luis Palmer, MD, I. Cerruti, MD, Francisco Lastiri, SciD

Blood (2006) 108 (11): 4680.

https://doi.org/10.1182/blood.V108.11.4680.4680

Published: 2006

Journal Articles

An International Multicentric Trial with Fludarabine Plus Cyclosphosphamide in B-Cell Chronic Lymphocytic Leukemia (CLL) “Up Front”: Second Interim Analysis.

Fernando Bezares, MD, Cecilio Jait, MD, Daniel Caviglia, MD, Daniel Bhar, MD, Andrea Rodriguez, MD, Norma Pilnik, MD, Virginia Prates, MD, Francisco Lastiri, MD, D. del Carpio, MD, Antonio A. Carrasco-Yalan, MD, Sergio Giralt, MD

Blood (2006) 108 (11): 4969.

https://doi.org/10.1182/blood.V108.11.4969.4969

Published: 2006

Journal Articles

Risk-Oriented Therapy in Adults Previously Untreated Hodgkin’s Lymphoma (HL) with ABVD Followed by Involved Field Radiotherapy (IFRT). Final Results of the Argentinian Group for Treatment of Acute Leukemia (GATLA) Phase III Study.

Santiago Pavlovsky, MD, PhD, Claudia S. Corrado, MD, Miguel A. Pavlovsky, MD, Virginia Prates, MD, Lucia Zoppegno, MD, Mario Giunta, MD, Ider Cerutti, MD, Elsa Palomino, MD, Fernando Pagani, MD, Francisco Lastiri, MD, Maria C. Narbaitz, MD, Fernando Cavagnaro, MD, Graciela Avila, MD

Blood (2006) 108 (11): 2474.

https://doi.org/10.1182/blood.V108.11.2474.2474

Published: 2006

Journal Articles

Risk-Adapted Therapy in Adults Previously Untreated Hodgkin’s Lymphoma (HL) with ABVD Followed by Involved Field Radiotherapy (IFRT).

Santiago Pavlovsky, MD PhD, Claudia S. Corrado, MD, Miguel A. Pavlovsky, MD, Mario Giunta, MD, Lucia Zoppegno, MD, Virginia Prates, MD, Francisco Lastiri, PhD, Ider Cerutti, MD, Maria C. Narbaitz, MD, Silvia Rudoy, MD, Fernando Cavagnaro, MD, Alejandra Kurchan, MD, Elsa Palomino, MD, Cesar Campo, MD

Blood (2004) 104 (11): 1310.

https://doi.org/10.1182/blood.V104.11.1310.1310

Published: 2004

NARROW

Safety and Efficacy Of Abbreviated Induction With Only 4 Cycles Of Fludarabine (F), Cyclophosphamide (C) and Rituximab (R) In Physically Fit Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Early Complete Remission (CR) With Undetectable Minimal Residual Disease (MDR)

PET -CT Adapted Therapy After 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma. Preliminary Results in 193 Patients

PET-CT Adapted Therapy After 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma. Interim Analysis in 173 Patients

Prospective Evaluation of the International Prognostic Score (IPS) in All Stages of Hodgkin’s Lymphoma Treated with ABVD Plus Involved-Field Radiotherapy (IFRT).

PET-CT Adapted Therapy after 3 Cycles of ABVD for All Stages of Hodgkin Lymphoma. Interim Analysis. Preliminary Results in 102 Patients

Fludarabine, Mitoxantrone and Dexamethasone for the First Line Treatment of Patients with Indolent Non-Hodgkin Lymphoma (NHL): GATLA First Interim Report (Grupo Argentino de Tratamiento de la Leucemia Aguda) .

An International Multicentric Trial with Fludarabine Plus Cyclosphosphamide in B-Cell Chronic Lymphocytic Leukemia (CLL) “Up Front”: Second Interim Analysis.

Risk-Oriented Therapy in Adults Previously Untreated Hodgkin’s Lymphoma (HL) with ABVD Followed by Involved Field Radiotherapy (IFRT). Final Results of the Argentinian Group for Treatment of Acute Leukemia (GATLA) Phase III Study.

Risk-Adapted Therapy in Adults Previously Untreated Hodgkin’s Lymphoma (HL) with ABVD Followed by Involved Field Radiotherapy (IFRT).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only